Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 3, 2011

Primary Completion Date

June 22, 2017

Study Completion Date

June 22, 2017

Conditions
Cancer
Interventions
DRUG

BMS-906024

Trial Locations (8)

3050

Local Institution, Parkville

30322

Winship Cancer Institute., Atlanta

37232

Vanderbilt-Ingram Cancer Center, Nashville

39216

University Of Mississippi Medical Center, Jackson

48201

Wayne State University, Detroit

77030

The Methodist Hospital Research Institute, Houston

90033

Anthony El-Khoueiry, Md, Los Angeles

M5G 2M9

Local Institution, Toronto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY